Abstract
Table S1. Patient and tumor characteristics. Table S2. Representativeness of study participants. Table S3. Clinical and histopathologic characteristics of individual patients. Table S4. Treatment related adverse events that occurred after first dose. Table S5. Adverse events related to immune checkpoint blockade. Table S6. Serious adverse events.